"

The sleep disorder market size is anticipated to reach over USD 1.31 billion by 2017. In 2017, the sleep apnea devices dominated the global market, in terms of revenue. Asia-Pacific is expected to be the Fastest growing contributor to the global market revenue in 2017.

Sleep is complex neurological state that helps in restoring energy level in the body. Alterations in the quality and pattern if sleep may cause sleep disorder. Sleep disorder is defined as a sleep problem, which is characterized by snoring, insomnia, depression, and sleep apnea. Recently, in a study it is found that the approximately more than 75% of Americans from the age of 25 to 59 suffer from sleep disorder in the U.S. Sleep disorder is basically characterize by the difficulty in falling asleep, daytime fatigue, lack of concentration, anxiety, and depression.

The sleep disorder market is primarily driven by the increasing number individual population suffering from various mental disorders, and rising awareness for the treatment of sleep disorders in the coming years. Furthermore, the changing life style of the people, and rising preference to the sedentary life style to also support the market growth in the coming years. Additionally, changing working culture, increasing geriatric population, and lack of quality sleep to also boost the market growth during the forecast period.

On the other side, increasing morbidity due to sleep disorder has increased the healthcare cost, and related side effects of the drugs, and increasing patent expiries that are used in treating sleep disorders which would impede the market growth during the forecast period. The treatment for include medication, better sleeping habits, and devices. Medicines such as, Hetlioz (tasimelteon) by Vanda Pharmaceuticals, Intermezzo (zolpidem tartrate sublingual tablet) by Transcept Pharmaceuticals, and Silenor (doxepin) by Somaxon Pharma are some of the FDA approved drugs that are observed to be beneficial during the treatment of sleep disorders.

The industry is segmented on the basis of disorder type, device, treatment, and geography. Based on disorder type, the market is bifurcated into sleep apnea, sleep breathing disorders, insomnia, hypersomnia, circadian rhythm disorders, parasomnia, and sleep movement disorders. on the basis of devices, the market is segmented into sleep apnea devices, sleep laboratories, and mattresses & pillows. By Treatment, the market is further bifurcated as psychiatric treatment, behavioral treatment, cognitive behavioral therapy, and medication therapy.

The market for sleep disorder in North America generated the highest revenue in 2017, and is expected to be the leading region globally during the forecast period. High number of patient population suffering the sleeping disorders is the primary factor accountable for the highest market growth. According to the US Department of Health and Human Services reports, approximately 20% Americans are suffering from sleep disorder. Thus, increasing demand for early treatments along with increasing patient pool, and growing patient awareness for proper diagnosis methods are factors boosting the growth in North America.

Asia Pacific is estimated to be the fastest growing region in terms of revenue. Growing awareness about sleep disorders and developing healthcare infrastructure are some of the factors that are projected to generate lucrative opportunities for the market in APAC.

The major key players operating in the Sleep Disorder industry include GlaxoSmithKline plc, Becton Dickson and Company, Cardinal Health, Natus Medical Incorporated Takeda Pharmaceutical Company Limited, Koninklijke Philips N.V., and Teva Pharmaceutical Industries Ltd. These companies launch new products and collaborate with other market leaders to innovate and launch new products to meet the increasing needs and requirements of consumers.

Polaris Market Research has segmented the global sleep disorders market on the basis of disorder, devices, treatment and region:

Sleep Disorder by Disorder Outlook (Revenue, USD Million, 2015 – 2026)

Insomnia
Hypersomnia
Insufficient Sleep Syndrome
Narcolepsy
Sleep Apnea
Sleep Breathing Disorders
Circadian Rhythm Disorders
Parasomnia
Sleep Eating Disorder
Sleep Terror
REM Sleep Behavior Disorder
Others
Sleep Movement Disorders
Restless Leg Syndrome
Sleep Leg Cramps

Sleep Disorder Devices Outlook (Revenue, USD Million, 2015 – 2026)

Sleep Apnea Devices
Sleep Laboratories
Mattresses & Pillows

Sleep Disorder Treatment Outlook (Revenue, USD Million, 2015 – 2026)

Psychiatric Treatment
Behavioral Treatment
Cognitive Behavioral Therapy
Medication Therapy
Prescription Drugs
OTC Drugs
Herbal Drugs

Sleep Disorder Regional Outlook (Revenue, USD Million, 2015 – 2026)

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Belgium
Russia
Netherlands
Rest of Europe
Asia-Pacific
China
India
Japan
Korea
Singapore
Malaysia
Indonesia
Thailand
Philippines
Rest of Asia-Pacific
Latin America
Brazil
Mexico
Argentina
Rest of LATAM
Middle East & Africa
UAE
Saudi Arabia
South Africa
Rest of MEA

"